AURA
HEALTHCAREAura Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving AURA Today?
No stock-specific AI insight has been generated for AURA yet. However, AURA was mentioned in the following AI insights:
52-Week Range
$8.29
Fundamentals
Trading
AURA News
20 articles- Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesYahoo Finance·May 5, 2026
- Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded WarrantsYahoo Finance·May 4, 2026
- Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·May 4, 2026
- Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment CompletionYahoo Finance·May 4, 2026
- Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?Yahoo Finance·Apr 22, 2026
- Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?Yahoo Finance·Apr 20, 2026
- Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?Yahoo Finance·Apr 10, 2026
- Auranova Announces Closing of Private Placement of Flow-Through SharesYahoo Finance·Apr 7, 2026
- Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Apr 6, 2026
- Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should KnowYahoo Finance·Apr 2, 2026
- Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi ProjectYahoo Finance·Apr 1, 2026
- Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 30, 2026
- Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?Yahoo Finance·Mar 20, 2026
- Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, OntarioYahoo Finance·Mar 18, 2026
- Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data TimelineMarketbeat·Mar 11, 2026
- Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen ConferenceMarketbeat·Mar 5, 2026
- Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?Yahoo Finance·Mar 4, 2026
- Aura Biosciences to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- Are Medical Stocks Lagging Assertio (ASRT) This Year?Yahoo Finance·Feb 16, 2026
- What Makes Aura Biosciences (AURA) a New Buy StockYahoo Finance·Feb 13, 2026
All 20 articles loaded
Price Data
52-Week Range
$8.29
Fundamentals
Trading
About Aura Biosciences Inc
Aura Biosciences Inc is an innovative clinical-stage biotechnology company dedicated to revolutionizing cancer treatment via its proprietary virus-like particle (VLP) technology. The company's lead investigational drug, AU-011, aims to selectively target and destroy ocular cancer cells while sparing adjacent healthy tissue, showcasing potential advancements in targeted therapies. With a strong clinical pipeline addressing critical unmet needs in oncology and a seasoned management team, Aura is well-positioned to make a significant impact in the oncology market. The company’s strategic partnerships further enhance its capabilities in driving forward new solutions in cancer treatment, aligning with the growing demand for precision medicine in the evolving healthcare landscape.